Pharming Group 将来の成長

Future 基準チェック /46

Pharming Group利益と収益がそれぞれ年間73.2%と9.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に10.9% 72.1%なると予測されています。

主要情報

73.2%

収益成長率

72.1%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	9.7%
将来の株主資本利益率	10.9%
アナリストカバレッジ	Low
最終更新日	04 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

OTCPK:PHGU.F - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	360	19	19	26	4
12/31/2025	320	1	5	11	4
12/31/2024	289	-10	2	7	4
9/30/2024	286	-18	0	0	N/A
6/30/2024	278	-13	-6	-6	N/A
3/31/2024	258	-11	18	-2	N/A
12/31/2023	245	-11	3	-17	N/A
9/30/2023	219	-22	-4	-24	N/A
6/30/2023	206	-16	5	-15	N/A
3/31/2023	202	-2	-3	-1	N/A
12/31/2022	206	14	20	22	N/A
9/30/2022	204	30	25	33	N/A
6/30/2022	202	21	15	26	N/A
3/31/2022	202	11	17	31	N/A
12/31/2021	199	16	21	38	N/A
9/30/2021	200	22	29	43	N/A
6/30/2021	200	31	40	52	N/A
3/31/2021	202	37	59	70	N/A
12/31/2020	212	38	68	84	N/A
9/30/2020	212	44	70	85	N/A
6/30/2020	202	46	59	93	N/A
3/31/2020	202	42	53	84	N/A
1/1/2020	189	41	49	74	N/A
9/30/2019	175	38	48	70	N/A
6/30/2019	175	34	59	63	N/A
3/31/2019	158	29	54	57	N/A
12/31/2018	155	29	42	46	N/A
9/30/2018	152	-29	57	63	N/A
6/30/2018	138	-44	N/A	61	N/A
3/31/2018	128	-80	N/A	52	N/A
12/31/2017	108	-91	N/A	46	N/A
9/30/2017	76	-53	N/A	14	N/A
6/30/2017	47	-47	N/A	-6	N/A
3/31/2017	31	-21	N/A	-13	N/A
12/31/2016	17	-18	N/A	-11	N/A
9/30/2016	12	-16	N/A	-18	N/A
6/30/2016	12	-15	N/A	-18	N/A
3/31/2016	13	-14	N/A	-18	N/A
12/31/2015	12	-11	N/A	-19	N/A
9/30/2015	29	8	N/A	-3	N/A
6/30/2015	27	9	N/A	-1	N/A
3/31/2015	23	10	N/A	-3	N/A
12/31/2014	26	-7	N/A	-3	N/A
9/30/2014	6	-29	N/A	-19	N/A
6/30/2014	6	-35	N/A	-16	N/A
3/31/2014	11	-35	N/A	-14	N/A
12/31/2013	9	-21	N/A	-11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PHGU.Fは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: PHGU.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: PHGU.F今後 3 年以内に収益を上げることが予想されます。

収益対市場: PHGU.Fの収益 ( 9.7% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: PHGU.Fの収益 ( 9.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PHGU.Fの自己資本利益率は、3年後には低くなると予測されています ( 10.9 %)。

Pharming Group 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Pharming Group N.V. Provides Revenue Guidance for 2024

Recent updates

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

Pharming Group N.V. announced that it expects to receive €100 million in funding

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe

Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST®

Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome

Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021

Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021

Pharming Group N.V. Announces Board Appointments

Pharming Group N.V. Announces Management Changes

Pharming Group N.V. Appoints Jeroen Wakkerman as Chief Financial Officer, Effective 16 November 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘